Piper Jaffray Cos. set a $41.00 price objective on Cellectis SA (NASDAQ:CLLS) in a research note released on Thursday. The brokerage currently has a buy rating on the stock.

Several other research firms also recently commented on CLLS. Jefferies Group reissued a buy rating on shares of Cellectis SA in a report on Friday, August 5th. Oppenheimer Holdings Inc. reissued an outperform rating and issued a $65.00 target price on shares of Cellectis SA in a report on Wednesday, July 27th. Finally, Zacks Investment Research raised Cellectis SA from a hold rating to a buy rating and set a $21.00 target price on the stock in a report on Thursday, October 20th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Cellectis SA presently has a consensus rating of Buy and an average target price of $42.33.

Shares of Cellectis SA (NASDAQ:CLLS) opened at 17.62 on Thursday. Cellectis SA has a 52-week low of $16.35 and a 52-week high of $34.99. The stock’s market capitalization is $622.57 million. The company has a 50-day moving average price of $0.00 and a 200-day moving average price of $0.00.

ILLEGAL ACTIVITY WARNING: “Cellectis SA (CLLS) Given a $41.00 Price Target by Piper Jaffray Cos. Analysts” was published by Daily Political and is the propert of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of United States and international copyright and trademark laws. The legal version of this piece of content can be read at http://www.dailypolitical.com/2016/11/30/cellectis-sa-clls-given-a-41-00-price-target-by-piper-jaffray-cos-analysts.html.

Several hedge funds and other institutional investors have recently made changes to their positions in CLLS. HighTower Advisors LLC boosted its stake in Cellectis SA by 0.3% in the second quarter. HighTower Advisors LLC now owns 13,440 shares of the company’s stock worth $357,000 after buying an additional 40 shares during the period. GAM Holding AG boosted its stake in Cellectis SA by 61.7% in the second quarter. GAM Holding AG now owns 15,220 shares of the company’s stock worth $405,000 after buying an additional 5,810 shares during the period. Lazard Asset Management LLC boosted its stake in Cellectis SA by 3.7% in the third quarter. Lazard Asset Management LLC now owns 285,175 shares of the company’s stock worth $6,867,000 after buying an additional 10,120 shares during the period. Susquehanna International Group LLP purchased a new stake in Cellectis SA during the third quarter worth approximately $281,000. Finally, Fiera Capital Corp purchased a new stake in Cellectis SA during the second quarter worth approximately $452,000. 19.79% of the stock is currently owned by hedge funds and other institutional investors.

Cellectis SA Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

5 Day Chart for NASDAQ:CLLS

Receive News & Ratings for Cellectis SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis SA and related companies with MarketBeat.com's FREE daily email newsletter.